ERBB2 and neoplasm: Higher tumor stages (III and IV), and the Basal and Her2 subtypes were significant (p ≤ 0.05) in contribution to disease progression in the final model, while margin status was not significant (p = 0.135, HR = 1.54, CI = 0.88 − 2.70).